The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01F | Monoclonal antibodies and antibody drug conjugates | |
| 4 | L01FB | CD22 (Clusters of Differentiation 22) inhibitors |
| Code | Title | |
|---|---|---|
| L01FB01 | Inotuzumab ozogamicin | |
| L01FB02 | Moxetumomab pasudotox |
| Active Ingredient | Description | |
|---|---|---|
| Inotuzumab ozogamicin |
Inotuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of a recombinant humanised IgG4 kappa CD22-directed monoclonal antibody that is covalently linked to N-acetyl-gamma-calicheamicin dimethylhydrazide. The small molecule, N-acetyl-gamma-calicheamicin, is a cytotoxic product. N-acetyl-gamma-calicheamicin is covalently attached to the antibody via an acid-cleavable linker. Activation of N-acetyl-gamma-calicheamicin dimethylhydrazide induces double-stranded DNA breaks, subsequently inducing cell cycle arrest and apoptotic cell death. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| BESPONSA Powder for concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| LUMOXITI Powder for concentrate solution for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| LUMOXITI Powder for solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
